#### 1 Comparative effectiveness of the BNT162b2 vs ChAdOx1 vaccine against Covid-19

#### 2 Authors

Junqing xie,<sup>1</sup> Shuo Feng,<sup>2</sup> Xintong Li,<sup>1</sup> Ester Gea-Mallorquí,<sup>3</sup> Albert Prats-Uribe,<sup>1</sup> Dani Prieto-

- 4 Alhambra<sup>1</sup>
- 5 1. Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
- 6 2. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
- 7 3. Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
- 8 Corresponding author: Prof Daniel Prieto-Alhambra, Botnar Research Centre, Windmill Road,
- 9 OX37LD, Oxford, UK, daniel.prietoalhambra@ndorms.ox.ac.uk

#### 10 Abstract

- 11 Although pivotal trials with varying populations and study methods suggest higher efficacy for mRNA
- 12 than adenoviral Covid-19 vaccines, no direct evidence is available. Here, we conducted a head-to-
- 13 head comparison of BNT162b2 versus ChAdOx1 against Covid-19. We analysed 235,181 UK Biobank
- participants aged 50 years or older and vaccinated with one or two doses of BNT162b2 or ChAdOx1.
- 15 People were followed from the vaccination date until 18/10/2021. Inverse probability weighting was
- 16 used to minimise confounding and the Cox models to derive hazard ratio. We found that, compared
- 17 with two doses of ChAdOx1, vaccination with BNT162b2 was associated with 30% lower risks of both
- 18 SARS-CoV-2 infection and related hospitalisation during the period dominated by the delta variant.
- 19 Also, this comparative effectiveness was consistent across several subgroups and persisted for at
- 20 least six months, suggesting no differential waning between the two vaccines. Our findings can
- 21 inform evidence-based Covid-19 vaccination campaigns and booster strategies.

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 23 Introduction

- 24 To date, four vaccines against the Coronavirus disease 2019 (Covid-19) have been approved for use
- 25 in the UK by the Medicines and Healthcare products Regulatory Agency: the Pfizer-BioNTech
- 26 BNT162b2, Moderna's mRNA-1273, Oxford-AstraZeneca's ChAdOx1, and Janssen's Ad26.CoV2.S.
- 27 Although phase 3 trials suggested that all four have high clinical efficacy, mRNA vaccines
- 28 demonstrated numerically greater efficacy than adenoviral-based ones: BNT162b2 reported 95%
- 29 efficacy against symptomatic covid-19,<sup>1</sup> mRNA-1273 94.1% efficacy,<sup>2</sup> whilst ChAdOx1 had 70.4%,<sup>3</sup>
- 30 and Ad26.CoV2.S had 66.9% efficacy.<sup>4</sup> However, notable differences in study designs made it difficult
- 31 to compare vaccine efficacy based on these trials, including different populations recruited in
- 32 different regions and at different times, diverse primary endpoint definitions, and heterogeneous
- 33 statistical analysis methods.
- 34 Specific for the two more widely utilized vaccines, BNT162b2 and ChAdOx1, several observational
- 35 studies have recently evaluated their effectiveness in multiple real-world settings from Israel,<sup>5</sup> the
- 36 UK,<sup>6</sup> and Spain,<sup>7</sup> amongst others. Although useful, none of these studies conducted head-to-head
- 37 comparisons of vaccine effectiveness. With the ongoing pandemic and rapid rollout of the Covid-19
- vaccination programme all over the world, evidence on their comparative performance has become
- 39 more crucial to inform policy decisions on optimizing vaccine implementation strategies, not only in
- 40 countries where greater coverage of the prime dose is urgently required or in countries where boost
- 41 doses and sequential immunization are being considered. Therefore, this study aimed to estimate
- 42 the comparative effectiveness of BNT162b2 vs ChAdOx1 vaccines against Covid-19 infection and
- 43 hospitalization in a large and rich prospective cohort of people aged 50 years or older.

44

#### 46 Results

## 47 Data linkage and study cohorts

- 48 During the one-dose enrolment period, 70,097 and 98,551 people received the first BNT162b2 and
- 49 ChAdOx1 Covid-19 vaccines, respectively. These figures were 67,813 and 89,030 accordingly for
- 50 people receiving the second dose during the two-dose enrolment period. Vaccine uptake over
- 51 calendar time in our study population is depicted in **Figure 1**.

## 52 Baseline characteristics

- 53 In the one-dose vaccine cohorts, people receiving BNT162b2 were slightly older (mean (sd) age:
- 54 71.35 (7.21) years) than those receiving ChAdOx1 (mean (sd) age: 71.06 (6.02) years ). Sex (44.5% vs
- 55 44.1% male) and ethnicity (91.2% vs 92.6% White) were comparable between the two groups. Little
- 56 difference was seen in the prevalence of medicines or comorbidities. The main differences between
- 57 cohorts were vaccination dates and socio-economic factors such as income (**Figure 2** and
- 58 **Supplementary Table 2**). Similar patterns of baseline characteristic differences were also seen in the
- 59 two-dose comparison cohorts (Figure 2 and Supplementary Table 3). All covariates were balanced
- after IPW weighting with an absolute standardised mean difference < 0.1, including the date of
- 61 vaccination.

## 62 Incidence and hazard ratio

- 63 Over the 14,630 and 20,714 person-years of follow-up for the one dose BNT162b2 and ChAdOx1
- recipient, 200 and 261 people tested positive for SARS-CoV-2, equivalent to incidence rates (IR) of
- 65 13.7 and 12.6/1,000 person-years, respectively, and an unadjusted hazard ratio (HR) of 1.08 (95%
- 66 0.90 1.30). After inverse probability weighting, the HR changed to 0.72 (95% 0.58 0.88), favouring
- 67 BNT162b2 in the overall population (**Table 1**). In contrast, the incidences of Covid-19 hospitalisation
- 68 were similar among the one dose BNT162b2 (IR: 3.07 per 1,000 person-years) and ChAdOx1 (IR: 2.17
- 69 per 1,000 person-years) cohorts, with no noticeable differences between both vaccine groups:
- 70 adjusted/weighted HR 0.87 (95% 0.53 1.41).
- After the second dose, 1,361/34,991 person-years (IR: 38.9 per 1,000 person-years) and
- 72 2,497/44,084 person-years (IR: 56.6 per 1,000 person-years) were identified positive for SARS-CoV-2
- 73 among BNT162b2 and ChAdOx1 recipients respectively. Unadjusted (0.72, 95% 0.57 0.91) and
- 74 adjusted HR (0.70, 95% 0.65 0.75) were almost identical, favouring BNT162b2 (**Table 1**). The rates
- of Covid-19 hospitalisation remained low in both cohorts, but higher amongst ChAdOx1 (IR: 4.55 per
- 76 1,000 person-years) compared to BNT162b2 recipients (IR: 3.47 per 1,000 person-years), with
- 77 adjusted HR of 0.71 (95% 0.55 0.90) favouring BNT162b2.
- 78 Kaplan–Meier curve of Covid-19 infection and hospitalisation
- 79 Kaplan–Meier curves stratified by vaccine depicted similar trends between Covid-19 infection and
- 80 hospitalisation. The cumulative incidence after the first dose increased rapidly in the early follow-up
- 81 but flattened later until 14 weeks after vaccination (Figure 3), corresponding to the calendar period
- 82 from January to March 2021 (Supplementary Figure 1). Conversely, the trend of cumulative
- 83 incidence was reversed for the two-dose cohorts, with a substantial increase starting 12 weeks after
- 84 the second dose (Figure 3), corresponding to the calendar period from June to October 2021
- 85 (Supplementary Figure 1). Changes in community transmission over time in the general population
- 86 of England and among UK Biobank participants are shown in **Supplementary Figure 1**.
- 87 Comparative effectiveness across sub-populations and over-time

- The risk of Covid-19 infection was consistently lower in people receiving two doses of BNT162b2
- 89 compared to those receiving two doses of ChAdOx1 across all strata. HRs ranged from 0.65 (95%
- 90 0.59 0.71) for females to 0.80 (95% 0.70 0.90) for oldest-old adults.
- 91 Notably, incidence rates of Covid-19 infection increased substantially during the study period, from
- 92 3.93 and 4.87 per 1,000 person-years at the 0–4-week window to 74.74 and 111.87 per 1,000
- 93 person-years at the >24-week window in BNT162b2 and ChAdOx1 cohorts, respectively. However,
- 94 as reflected by HRs, the comparative risks were stable for at least six months (Figure 4). Although a
- 95 similar pattern was observed for Covid-19 hospitalisation, power was limited for the time-split
- analysis, in particular for the 0–4-week window (HR: 0.16, 95% 0.02 1.54) and 4–8-week window
- 97 (HR: 2.48, 95% 0.16 39.66), due to the extremely rare events observed in the first few weeks after
- 98 the second vaccination (Figure 4).
- 99 Negative control and sensitivity analyses
- 100 Adjusted hazard ratios for proposed negative clinical outcomes according to vaccine received among
- the one dose cohort were 1.01 (0.95 to 1.17) for limb pain, 0.93 (0.82 to 1.05) for fracture, and 0.88
- 102 (0.51 to 1.51) for peptic ulcer.
- 103 The main results were consistent in the propensity score-matched cohorts with slightly wider
- 104 confidence intervals (**Supplementary Table 4**).

#### 105 Main tables and figures



106 Figure 1: The number of people receiving either BNT162b2 or ChAdOx1 Covid-19 vaccine in the study cohort from Dec 01, 2020 to Sep 21, 2021.

107

108 The rectangle background with grey color depicts the vaccination anchor windows. Only people who received study vaccines within the anchor windows

were included for the comparative analysis. We defined the 2<sup>rd</sup> to 8<sup>th</sup> (Jan 11, 2021 to Feb 28, 2021) and 12<sup>th</sup> to 18<sup>th</sup> (March 22, 2021 to May 9, 2021)

110 calendar weeks as the two anchor windows for the one-dose and two-dose cohorts, respectively. The decision-making for these anchor windows was based

111 on (1) there were both BNT162b2 and ChAdOx1 vaccines delivered in each epidemiological week of the window, (2) numbers of the two vaccines were

generally comparable, and (3) UK's policy on the gap between the first and second dose was 10 to 12 weeks for both vaccines.



#### 114 Figure 2: Balance of baseline covariates for the one dose and two doses cohorts, before and after weighting.

Standardized mean difference

in the propensity score. (B, C) distribution of age and % obesity according to vaccine received

# 120 Table 1: Incidence rate and hazard ratio of COIVD-19 infection and hospitalisation following one and two doses of vaccines.

	BNT162b2			ChAdOx1				
	Vaccination	Cases	Rate, per	Vaccination	Cases	Rate, per	Unadjusted	Adjusted hazard
	years		1000 PYs	years		1000 PYs	hazard ratio	ratio
One dose								
Covid-19 infection	14630	200	13.7	20714	261	12.6	1.08 (0.90 - 1.30)	0.72 (0.58 - 0.88)
Covid-19 hospitalisation	14654	45	3.07	20746	45	2.17	1.41 (0.95 - 2.09)	0.87 (0.53 - 1.41)
Two doses								
Covid-19 infection	34991	1361	38.9	44084	2497	56.6	0.72 (0.57 - 0.91)	0.70 (0.65 - 0.75)
Covid-19 hospitalisation	35176	122	3.47	44421	202	4.55	0.66 (0.62 - 0.71)	0.71 (0.55 - 0.90)

122 PYs: person-years



## 125 Figure 3: Kaplan-Meier cumulative incidence curves of Covid-19 infection and hospitalization after one and two doses of vaccines.

126

127 Notes: The different Y-axis scales for Covid-19 infection and hospitalisation outcomes. The longest follow-up was 14 weeks after the first dose and 30 weeks

128 after the second dose of the vaccine.

129

#### 131 Figure 4: Comparative effectiveness of two doses BNT162b2 vs ChAdOx1 vaccine on Covid-19 infection and hospitalisation across key subgroups and





133 Notes: The different X-axis range of incidence rate for the Covid-19 infection and hospitalisation outcomes (unit, per 1000 person-years). Hazard ratios for

134 Covid-19 hospitalisation were truncated at 0.2 (lowest) and 2 (highest).

#### 139 Discussion

140 Among adults aged 50 years and older, we found that people receiving two doses of BNT162b2

- 141 vaccine had 30% lower risks of both Covid-19 diagnosis and related hospital admission, compared
- 142 with those vaccinated with ChAdOx1. A similar difference was also observed among the one dose
- recipients, yet, only for Covid-19 diagnosis. Notably, the two-dose comparative effectiveness was
- 144 consistent across several high-risk groups, such as oldest-old,<sup>7</sup> male,<sup>8</sup> ethnic minority<sup>9</sup> and those with
- 145 overweight or obesity,<sup>10</sup> and persisted over time for over six months.
- 146 To date, only two Phase 2 randomized controlled trial has directly compared the efficacy of mRNA
- 147 with adenovirus-based Covid-19 vaccines by using immunogenic endpoints. Liu et al.<sup>11</sup> found that
- the BNT162B2-BNT162B2 appeared more immunogenic than the ChAdOx1-ChAdOx1 schedule, with
- 149 higher levels of antibodies at 28 days after the first and second dose. A similar finding was reported
- 150 in the Borobia et al. study comparing the heterologous BNT162B2-ChAdOx1 and the homogenous
- 151 ChAdOx1-ChAdOx1 vaccine regimens.<sup>12,13</sup> In line with this evidence, our study showed a lower risk of
- 152 Covid-19 outcomes in people vaccinated with BNT162b2 overall and across subgroups.
- However, a recent preprint study by Hulme et al.<sup>14</sup> showed no difference among recipients of these 153 two vaccines regarding the risk of SARS-CoV-2 positive test, COVID-19 related accident & emergency 154 155 attendance and hospital admission. Several fundamental factors might explain the disagreement 156 with our results. First, Hulme's study only included health and social care workers who are more likely to be exposed to SARS-CoV-2 than our cohort: a community-based "healthy volunteer" 157 158 population,<sup>15</sup> which was corroborated by the higher infection rate in their study (58 per 1,000 159 person-years) compared to ours (~13 per 1,000 person-years) during the first few weeks following the first dose. Second, both our and Hulme's studies found that, on average, vaccination with 160 161 BNT162B2 happened earlier than ChAdOx1. Given the variation over time in community 162 transmission in England (Supplementary Figure 1), insufficient control for vaccination date can result 163 in an inflated risk of COVID-19 amongst BNT162B2 recipients. Informed by this, we observed a 164 substantial change of hazard ratio after the complete alignment of the first vaccination date by 165 weighting in our study. Thirdly, Hulme's risk assessment period started from the first dose (January 166 to February 2021) and ended on 13 June 2021, reflecting a mixed effect of one and two doses of
- 167 vaccines.
- Finally, our data for the first time demonstrated that the observed differences did not attenuate
  over time, verifying the hypothesis from a few recent preprint studies.<sup>16,17</sup>
- 170 Strengths and limitations
- 171 The leading challenges in estimating vaccine effectiveness with observational data lies in
- 172 confounding by indication and potentially differential testing rates between exposed vaccinated and
- 173 unvaccinated populations.<sup>18,19</sup> However, our study minimized the impact of such differences by
- 174 comparing two vaccines and restricting the analysis to a period when both vaccines were available
- and had a similar national delivery. UK data are ideal for comparative effectiveness research into
- 176 Covid-19 vaccines, as both BNT162b2 and ChAdOx1 were rolled out simultaneously for the target
- 177 population (adults  $\geq$  50 years) included in our analyses.<sup>20 21,22</sup>.
- 178 However, additional limitations remain. Information on a few participants' characteristics was
- 179 collected ten years ago and may have changed since then. However, given that all people at the
- 180 cohort recruitment were already middle-aged or older adults (40-69 years old), we expected any
- 181 changes in those features such as socio-economic status and education are likely to be minor or
- 182 unrelated to the choice of vaccine types. Admittedly, misclassification of covariates could bias the

- 183 genuine association towards the null and lead to underestimating the comparative vaccine
- 184 effectiveness. Our study has several unique strengths. First, the granularity of UK Biobank data and
- 185 comprehensive linkage to external data sources allowed us to measure and control for an extensive
- array of confounders, including demographics, socio-economic deprivation, comorbidity, and
- 187 medication usage. Our negative control outcome analyses provided reassurance that no significant
- residual confounding remained after adjusting the mentioned covariates using IPW methods.
- 189 Secondly, the proposed study outcomes (Covid-19 and related hospitalization) were identified
- 190 through linkage to official national databases of tests and hospital inpatient data, minimising the risk
- of misclassification. Finally, the sample size of our cohort triplicated that of the largest phase III
- trials, enabling us to detect differences in hospital admission rates, which seemed underpowered in
- 193 randomized trials.

### 194 Conclusions

- 195 Our findings support evidence from pivotal trials suggesting that BNT162b2 provides additional
- 196 protection against Covid-19 and hospitalisation than ChAdOx1 vaccination. For the first time, we
- 197 demonstrated that this comparative effectiveness endured over six months when the Delta variant
- 198 was predominant, and community transmission kept increasing in the UK. These findings highlight
- 199 the importance of continuous monitoring of the effectiveness of different vaccines against emerging
- 200 SARS-CoV-2 variants to inform future booster campaigns and vaccine combinations strategies.
- 201
- 202

#### 204 Methods

#### 205 Study population and design

- 206 We used data from the UK Biobank (UKBB) cohort, a prospective study of approximately 500,000
- individuals aged between 40 and 69 at baseline recruited in 2007-2010 from England (89%), Scotland
- 208 (7%) and Wales (4%). All participants provided comprehensive information on socio-demographic,
- 209 lifestyle, and health-related factors, which has been described in detail elsewhere.<sup>23</sup>
- 210 In this study, we analysed participants from England, as vaccination data for Scotland and Wales
- 211 were not available. Although vaccination started in early December 2020 in the UK, we restricted our
- analyses to periods when both vaccines were rolled out to maximise comparability in individual- and
- 213 population-level characteristics, including indication for vaccination, ongoing public health
- restrictions and predominant virus variants. With this in mind, we enrolled one-dose and two-dose
- 215 Covid-19 vaccine cohorts covering from Jan 11, 2021 to Feb 28, 2021, and from March 22, 2021 to
- 216 May 9, 2021 respectively. Participants with primary care records generated using the TTP software,
- 217 which did not contain a specific vaccine type, were excluded.

#### 218 Data sources

- 219 Data linkage
- 220 Several external data sources have been linked to UK Biobank to enable Covid-19 research, including
- 221 primary care electronic health records, hospital admissions data from Hospital Episode Statistics
- 222 (HES), and Covid-19 tests from Public Health England (PHE).<sup>24</sup> Data coverage for each data source is
- listed in the **Supplementary Methods**.
- 224 Vaccination status
- 225 Vaccination status was obtained from GP prescription records, including the date of receipt of each
- 226 dose and the vaccine brand. We used dm+d codes (Dictionary of medicines and devices used across
- the UK's National Health Service) to identify BNT162b2 [39115611000001103] and ChAdOx1
- 228 [39114911000001105] Covid-19 vaccination.
- 229 Study outcomes
- 230 In the UK, people at any age with any of these three Covid-19 symptoms (a high temperature, a new
- and continuous cough, or loss or change in the sense of smell or taste) are recommended to take a
- free Polymerase-chain-reaction (PCR) test by ordering a self-swab home PCR test kit or booking an
- appointment at a walk-in or drive-through test site. People could also access this service if they were
- at high risk of infection, e.g., close contact with a case (see <u>https://www.gov.uk/get-coronavirus-test</u>
- for details). All these tests were recorded by PHE and linked to UK Biobank, providing information on
- test dates and results. In this study, we defined infection as having a positive PCR test for SARS-CoV-
- 237 2; and Covid-19 hospitalization (infection requiring hospital admission) based on the UKBB derived
- algorithm described in the Supplementary Methods.
- 239 Covariates
- 240 We assessed multiple characteristics potentially associated with Covid-19 risk and/or vaccination,
- 241 therefore considered as confounders. Study covariates included socio-demographics (age, sex,
- 242 ethnicity), socio-economic status (index of multiple deprivations, education levels), physical
- 243 measurements (body mass index), healthcare resource use (prescribed medications and the number
- of hospital admissions three years before the vaccination date), and comorbidities. The calendar

week of receipt of the Covid-19 vaccine was also included as it affected the probability of receivingdifferent vaccines and infection risk (through changes in community transmission level).

### 247 Statistical analyses

248 The outcome risk assessment window for the one-dose cohort went from receiving the first dose to

- the earliest of outcome occurrence, receiving the second dose, or 14 weeks after the vaccination.
- For the two-dose cohort, follow-up was from receiving the second dose to outcome occurrence or end of the study (18/10/2021)
- 251 end of the study (18/10/2021).
- 252 We used the propensity score-based inverse probability of treatment weighting (IPW) to minimise
- 253 confounding.<sup>25</sup> The specification of propensity score modelling was described in **Supplementary**
- 254 **Methods**. We generated Kaplan-Meier plots to depict the cumulative incidence of outcome over
- time in each cohort. We applied Cox proportional hazards regression with robust variance
- estimators to derive average hazard ratio (HR) and calculated incidence rates using weighted counts
- and follow-up time. We assessed the proportionality of hazards in the Cox models by visuallyinspecting scaled Schoenfeld residuals.
- 259 To evaluate for potential heterogeneity of the comparative effectiveness among specific
- 260 demographic subgroups and overtime after the second dose, we performed several secondary
- analyses by including multiplicative interaction terms between the vaccine types and the following
- categories separately: age (50-75 years or > 75 years), sex (male or female), ethnicity (white or other
- ethnic groups), BMI (< 25 vs  $\ge$  25), and four weeks' consecutive time intervals.
- 264 We conducted the negative control experiment to assess potential residual (unobserved)
- 265 confounding. Three clinical outcomes (limb pain, fracture, and peptic ulcer events) were pre-
- specified and should not be associated with vaccination status (BNT162b2 vs ChAdOx1) if potential
- 267 confounders have been adequately controlled for.
- 268 Finally, we performed a sensitivity analysis using propensity score 1:1 matching without
- 269 replacement. Specifically, we set a caliper of width equal to 0.2 of the standard deviation of the logit
- 270 of the propensity score.<sup>26</sup> We used R version 3.5.1 for all analyses.

#### 271 Supplementary items





Notes: The data for weekly Covid-19 cases and SARS-CoV-2 variants of concern in England were from the Public Health England
 (https://coronavirus.data.gov.uk/).

## **Supplementary Table 2: Baseline characteristics of the one dose cohorts.**

	Before weighting		After weighting	
	BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
Number	70097	98551	167938	167917
Previous infection (%)	1843 ( 2.6)	2649 ( 2.7)	4635.7 ( 2.8)	4662.1 ( 2.8)
Vaccination calendar week (%)				
Week2	12224 (17.4)	3127 ( 3.2)	15716.6 ( 9.4)	14681.5 ( 8.7)
Week3	15591 (22.2)	15728 (16.0)	31194.2 (18.6)	31220.5 (18.6)
Week4	14783 (21.1)	16990 (17.2)	32056.9 (19.1)	32096.3 (19.1)
Week5	7655 (10.9)	24264 (24.6)	31629.9 (18.8)	31957.0 (19.0)
Week6	7573 (10.8)	19492 (19.8)	26858.2 (16.0)	27070.1 (16.1)
Week7	5907 ( 8.4)	11282 (11.4)	16731.3 (10.0)	17059.5 (10.2)
Week8	6364 ( 9.1)	7668 ( 7.8)	13751.8 ( 8.2)	13832.5 ( 8.2)
Demographics				
Age, mean (sd)	71.35 (7.21)	71.06 (6.02)	71.09 (6.68)	71.11 (6.48)
Sex, male (%)	31203 (44.5)	43432 (44.1)	74111.1 (44.1)	74156.6 (44.2)
BMI, mean (sd)	27.56 (4.78)	27.46 (4.76)	27.51 (4.77)	27.51 (4.78)
Ethnicity (%)				
Asian or Asian British	1479 ( 2.1)	1563 ( 1.6)	3112.1 ( 1.9)	3085.9 ( 1.8)
Black or Black British	1136 ( 1.6)	1138 ( 1.2)	2311.8 ( 1.4)	2220.0 ( 1.3)
Chinese	224 ( 0.3)	263 ( 0.3)	478.5 ( 0.3)	481.6 ( 0.3)
Do not know	30 ( 0.0)	41 ( 0.0)	71.5 ( 0.0)	75.7 ( 0.0)
Mixed	397 ( 0.6)	460 ( 0.5)	851.1 ( 0.5)	840.7 ( 0.5)
Other ethnic group	657 ( 0.9)	703 ( 0.7)	1374.9 ( 0.8)	1363.6 ( 0.8)
Prefer not to answer	2248 ( 3.2)	3102 ( 3.1)	5267.6 ( 3.1)	5257.8 ( 3.1)
White	63926 (91.2)	91281 (92.6)	154471.3 (92.0)	154592.2 (92.1
Education (%)				
None of the above	12247 (17.5)	16502 (16.7)	28750.7 (17.1)	28763.7 (17.1)
Prefer not to answer	2101 ( 3.0)	2323 ( 2.4)	4455.3 ( 2.7)	4320.0 ( 2.6)
College or university degree	21484 (30.6)	31157 (31.6)	52075.8 (31.0)	52190.1 (31.1)
A levels as levels or equivalent	7498 (10.7)	11054 (11.2)	18481.5 (11.0)	18474.9 (11.0)
O levels gcs es or equivalent	14812 (21.1)	20890 (21.2)	35573.0 (21.2)	35668.3 (21.2)

Cs es or equivalent	3473 ( 5.0)	4776 ( 4.8)	8245.5 ( 4.9)	8268.9 ( 4.9)
Nvq or hnd or hnc or equivalent	4605 ( 6.6)	6501 ( 6.6)	11099.1 ( 6.6)	11120.0 ( 6.6)
Other professional qualifications	3877 ( 5.5)	5348 ( 5.4)	9257.9 ( 5.5)	9111.5 ( 5.4)
Indices of Multiple Deprivation, mean (sd)				
Townsend deprivation index	17.70 (13.96)	16.49 (13.37)	17.08 (13.57)	17.01 (13.73)
Income score	0.12 (0.10)	0.11 (0.09)	0.11 (0.09)	0.11 (0.10)
Employment score	0.09 (0.06)	0.08 (0.06)	0.09 (0.06)	0.09 (0.06)
Health score	-0.11 (0.89)	-0.18 (0.88)	-0.13 (0.89)	-0.14 (0.89)
Education score	14.61 (14.90)	14.13 (14.83)	14.40 (14.74)	14.39 (15.02
Housing score	19.94 (9.95)	19.80 (9.98)	19.70 (9.84)	19.69 (9.97)
Crime score	-0.04 (0.78)	-0.09 (0.77)	-0.07 (0.77)	-0.07 (0.77)
Medications (past three years)				
Lipid lowering drugs	33093 (47.2)	43266 (43.9)	76151.4 (45.3)	75957.6 (45.2
RAS inhibitors	21956 (31.3)	29023 (29.4)	50602.1 (30.1)	50609.0 (30.1
Other anti-hypertensives	11158 (15.9)	14517 (14.7)	25459.6 (15.2)	25458.1 (15.2
Proton pump inhibitors	30579 (43.6)	41572 (42.2)	72068.6 (42.9)	71994.1 (42.9
Diabetes medicines	6666 ( 9.5)	8288 ( 8.4)	14982.9 ( 8.9)	14899.5 ( 8.9)
Antidepressants	14515 (20.7)	20199 (20.5)	34836.6 (20.7)	34987.6 (20.8
Systemic glucocorticoids	9282 (13.2)	12919 (13.1)	22129.9 (13.2)	22245.6 (13.2
Antithrombotic	11799 (16.8)	15061 (15.3)	26856.6 (16.0)	26832.6 (16.0
Anticoagulants	3110 ( 4.4)	4020 ( 4.1)	7099.6 ( 4.2)	7130.8 ( 4.2)
Immunosuppressants excl corticosteroids	1447 ( 2.1)	2017 ( 2.0)	3448.5 ( 2.1)	3492.0 ( 2.1)
Antineoplastic agents	180 ( 0.3)	251 ( 0.3)	413.7 ( 0.2)	413.4 ( 0.2)
Hospital admission frequency (past three years)	1.38 (5.52)	1.34 (5.25)	1.37 (6.36)	1.37 (5.12)
Charlson comorbidity components (past years)				
Diabetes (uncomplicated)	9193 (13.1)	11657 (11.8)	20797.9 (12.4)	20800.9 (12.4
COPD	14156 (20.2)	19433 (19.7)	33547.1 (20.0)	33504.9 (20.0
Chronic kidney disease	7449 (10.6)	9368 ( 9.5)	16714.7 (10.0)	16713.1 (10.0
Congestive heart failure	1473 ( 2.1)	1893 ( 1.9)	3344.1 ( 2.0)	3370.8 ( 2.0)
Cancer	10807 (15.4)	14483 (14.7)	25028.3 (14.9)	24975.7 (14.9
Dementia	681 ( 1.0)	959 ( 1.0)	1731.3 ( 1.0)	1827.9 ( 1.1)
Cerebrovascular disease	2799 ( 4.0)	3498 ( 3.5)	6356.5 ( 3.8)	6324.4 ( 3.8)
Diabetes (end-organ damage)	3821 ( 5.5)	4755 ( 4.8)	8556.7 ( 5.1)	8526.5 ( 5.1)

Peripheral vascular disease	1459 ( 2.1)	1857 ( 1.9)	3276.3 ( 2.0)	3287.2 ( 2.0)
Liver disease (moderate to severe)	279 ( 0.4)	384 ( 0.4)	631.3 ( 0.4)	646.1 ( 0.4)
Peptic ulcer	2151 ( 3.1)	2877 ( 2.9)	5081.0 ( 3.0)	5018.4 ( 3.0)
Rheumatoid arthritis	3118 ( 4.4)	4177 ( 4.2)	7266.1 ( 4.3)	7265.0 ( 4.3)
Myocardial infarction	2573 ( 3.7)	3254 ( 3.3)	5890.7 ( 3.5)	5866.9 ( 3.5)
AIDS	137 ( 0.2)	183 ( 0.2)	320.8 ( 0.2)	310.5 ( 0.2)
Malignant cancer	370 ( 0.5)	502 ( 0.5)	859.2 ( 0.5)	836.4 ( 0.5)
Liver disease (mild)	452 ( 0.6)	650 ( 0.7)	1105.4 ( 0.7)	1110.2 ( 0.7)
Hemiplegia	98 ( 0.1)	147 ( 0.1)	263.2 ( 0.2)	250.8 ( 0.1)

# 

## 279 Supplementary Table 3: Baseline characteristics of the two dose cohorts.

	Before weighting		After weighting	
	BNT162b2	ChAdOx1	BNT162b2	ChAdOx1
Number	67813	89030	156301	156952
Previous infection (%)	2539 ( 2.9)	1818 ( 2.7)	4518.5 ( 2.9)	4498.7 ( 2.9)
Vaccination calendar week (%)				
Week12	8299 (12.2)	3972 ( 4.5)	12366.1 ( 7.9)	12606.7 ( 8.0)
Week13	13558 (20.0)	4373 ( 4.9)	18073.8 (11.6)	17812.4 (11.3)
Week14	12976 (19.1)	13900 (15.6)	26803.0 (17.1)	26791.8 (17.1)
Week15	13365 (19.7)	16445 (18.5)	29957.9 (19.2)	29935.1 (19.1)
Week16	6892 (10.2)	21591 (24.3)	28278.7 (18.1)	28468.5 (18.1)
Week17	7037 (10.4)	16945 (19.0)	23698.1 (15.2)	23941.3 (15.3)
Week18	5686 ( 8.4)	11804 (13.3)	17123.5 (11.0)	17396.8 (11.1)
Demographics				
Age, mean (sd)	72.47 (6.97)	71.51 (5.98)	71.80 (6.74)	71.81 (6.18)
Sex, male (%)	29825 (44.0)	39250 (44.1)	68880.5 (44.1)	69199.6 (44.1)
BMI, mean (sd)	27.47 (4.67)	27.46 (4.74)	27.50 (4.72)	27.50 (4.75)
Ethnicity (%)				
Asian or Asian British	1279 ( 1.9)	1348 ( 1.5)	2656.8 ( 1.7)	2641.7 ( 1.7)
Black or Black British	924 ( 1.4)	969 ( 1.1)	1957.9 ( 1.3)	1921.4 ( 1.2)
Chinese	185 ( 0.3)	225 ( 0.3)	405.8 ( 0.3)	409.4 ( 0.3)
Do not know	26 ( 0.0)	37 ( 0.0)	68.3 ( 0.0)	66.4 ( 0.0)
Mixed	345 ( 0.5)	408 ( 0.5)	730.0 ( 0.5)	735.3 ( 0.5)
Other ethnic group	560 ( 0.8)	613 ( 0.7)	1182.2 ( 0.8)	1171.0 ( 0.7)
Prefer not to answer	2143 ( 3.2)	2737 ( 3.1)	4807.1 ( 3.1)	4881.0 ( 3.1)
White	62351 (91.9)	82693 (92.9)	144492.9 (92.4)	145126.1 (92.5)
Education (%)				
None of the above	12648 (18.7)	15435 (17.3)	28036.2 (17.9)	28234.6 (18.0)
Prefer not to answer	2031 ( 3.0)	2116 ( 2.4)	4097.4 ( 2.6)	4059.5 ( 2.6)
College or university degree	20513 (30.2)	27567 (31.0)	47638.2 (30.5)	47836.8 (30.5)
A levels as levels or equivalent	7069 (10.4)	9848 (11.1)	16888.3 (10.8)	16951.9 (10.8)
O levels gcs es or equivalent	14183 (20.9)	19030 (21.4)	33181.6 (21.2)	33314.8 (21.2)

Cs es or equivalent	2970 ( 4.4)	4142 ( 4.7)	7166.0 ( 4.6)	7180.5 ( 4.6)
Nvq or hnd or hnc or equivalent	4440 ( 6.5)	5916 ( 6.6)	10415.2 ( 6.7)	10483.2 ( 6.7)
Other professional qualifications	3959 ( 5.8)	4976 ( 5.6)	8878.2 ( 5.7)	8891.1 ( 5.7)
Indices of Multiple Deprivation, mean (sd)				
Townsend deprivation index	17.35 (13.69)	16.39 (13.27)	17.00 (13.51)	16.97 (13.62)
Income score	0.11 (0.09)	0.11 (0.09)	0.11 (0.09)	0.11 (0.09)
Employment score	0.09 (0.06)	0.08 (0.06)	0.09 (0.06)	0.09 (0.06)
Health score	-0.12 (0.89)	-0.18 (0.88)	-0.14 (0.88)	-0.14 (0.88)
Education score	14.39 (14.77)	14.10 (14.80)	14.35 (14.72)	14.35 (14.96)
Housing score	19.85 (9.90)	19.66 (9.92)	19.64 (9.80)	19.66 (9.97)
Crime score	-0.05 (0.78)	-0.09 (0.77)	-0.07 (0.77)	-0.07 (0.77)
Medications (past three years)				
Lipid lowering drugs	33138 (48.9)	40248 (45.2)	73220.9 (46.8)	73457.8 (46.8)
RAS inhibitors	21768 (32.1)	26794 (30.1)	48369.8 (30.9)	48521.5 (30.9)
Other anti-hypertensives	11297 (16.7)	13489 (15.2)	24636.9 (15.8)	24732.6 (15.8)
Proton pump inhibitors	30074 (44.3)	38128 (42.8)	68201.9 (43.6)	68396.9 (43.6)
Diabetes medicines	6168 ( 9.1)	7556 ( 8.5)	13866.2 ( 8.9)	13854.3 ( 8.8)
Antidepressants	13877 (20.5)	18277 (20.5)	32391.9 (20.7)	32511.1 (20.7)
Systemic glucocorticoids	9126 (13.5)	11585 (13.0)	20797.3 (13.3)	20784.2 (13.2)
Antithrombotic	11903 (17.6)	14077 (15.8)	26024.1 (16.6)	26049.1 (16.6)
Anticoagulants	3392 ( 5.0)	3969 ( 4.5)	7289.0 ( 4.7)	7271.8 ( 4.6)
Immunosuppressants excl corticosteroids	1357 ( 2.0)	1823 ( 2.0)	3216.2 ( 2.1)	3222.4 ( 2.1)
Antineoplastic agents	185 ( 0.3)	232 ( 0.3)	411.4 ( 0.3)	398.8 ( 0.3)
Hospital admission frequency (past three years)	1.39 (5.82)	1.32 (5.02)	1.37 (6.36)	1.36 (4.89)
Charlson comorbidity components (past years)				
Diabetes (uncomplicated)	8663 (12.8)	10667 (12.0)	19443.3 (12.4)	19495.5 (12.4)
COPD	13737 (20.3)	17715 (19.9)	31566.4 (20.2)	31582.3 (20.1)
Chronic kidney disease	7746 (11.4)	8924 (10.0)	16513.0 (10.6)	16558.8 (10.6)
Congestive heart failure	1548 ( 2.3)	1814 ( 2.0)	3355.0 ( 2.1)	3359.2 ( 2.1)
Cancer	10937 (16.1)	13601 (15.3)	24305.2 (15.6)	24366.2 (15.5)
Dementia	820 ( 1.2)	1004 ( 1.1)	1871.1 ( 1.2)	1942.2 ( 1.2)
Cerebrovascular disease	2860 ( 4.2)	3327 ( 3.7)	6199.3 ( 4.0)	6173.1 ( 3.9)
Diabetes (end-organ damage)	3638 ( 5.4)	4411 ( 5.0)	8099.5 ( 5.2)	8084.2 ( 5.2)

1513 ( 2.2)	1760 ( 2.0)	3258.4 ( 2.1)	3256.7 ( 2.1)
258 ( 0.4)	348 ( 0.4)	605.6 ( 0.4)	606.2 ( 0.4)
2190 ( 3.2)	2684 ( 3.0)	4912.0 ( 3.1)	4898.0 ( 3.1)
3225 ( 4.8)	3939 ( 4.4)	7172.6 ( 4.6)	7153.7 ( 4.6)
2541 ( 3.7)	3053 ( 3.4)	5663.6 ( 3.6)	5663.5 ( 3.6)
131 ( 0.2)	164 ( 0.2)	294.3 ( 0.2)	288.0 ( 0.2)
352 ( 0.5)	462 ( 0.5)	789.2 ( 0.5)	804.3 ( 0.5)
421 ( 0.6)	579 ( 0.7)	1005.7 ( 0.6)	1022.9 ( 0.7)
90 ( 0.1)	123 ( 0.1)	225.5 ( 0.1)	222.0 ( 0.1)
	1513 ( 2.2) 258 ( 0.4) 2190 ( 3.2) 3225 ( 4.8) 2541 ( 3.7) 131 ( 0.2) 352 ( 0.5) 421 ( 0.6) 90 ( 0.1)	$\begin{array}{cccc} 1513 (2.2) & 1760 (2.0) \\ 258 (0.4) & 348 (0.4) \\ 2190 (3.2) & 2684 (3.0) \\ 3225 (4.8) & 3939 (4.4) \\ 2541 (3.7) & 3053 (3.4) \\ 131 (0.2) & 164 (0.2) \\ 352 (0.5) & 462 (0.5) \\ 421 (0.6) & 579 (0.7) \\ 90 (0.1) & 123 (0.1) \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

282 Supplementary Table 4: Sensitivity analysis (propensity score matching)

	BNT162b2 vs ChAdOx1			
	Number	Events	Incidence	HRs
After first-dose				
Covid-19 infection	58676/ 58676	154/ 193	12.6/ 15.7	0.80 (0.65 - 0.99)
Covid-19 hospitalization	58676/ 58676	29/ 32	2.36/ 2.60	0.91 (0.55 - 1.51)
After second-dose				
Covid-19 infection	54422/ 54422	1089/ 1582	39.5/ 57.6	0.69 (0.63 - 0.74)
Covid-19 hospitalization	54422/ 54422	93/ 142	3.35/ 5.13	0.65 (0.50 - 0.85)

#### 285 Supplementary Methods

### 286 Sources and timelines for data availability



287

288 The baseline recruitment data includes detailed demographic, socioeconomic, lifestyle factors, and physical activities information. The HES data includes

289 hospital administration, operations and diagnoses information. The GP data includes diagnoses and prescription information. Of note, the Covid-19

vaccination has been integrated into EMIS GP's prescription records but not into the TPP. The PHE data includes Covid-19 test results.

#### 292 Construction of the inpatient indicator for UKBB participants

293 The construction of the "origin" field is based on information provided on the specimen request form. If the specimen was marked as being from an acute

- 294 (emergency) care provider, an A&E department, an inpatient location, or resulted from health care associated infection, it is recorded by PHE as an
- inpatient sample. Tests marked as being from "Healthcare Worker Testing" are never recorded as inpatient samples, though some may also carry an acute



flag.

The aim of designating inpatient status for the SARS-CoV-2 test was to indicate severity of Covid-19 infection. SARS-CoV-2 tests taken in hospital can be undertaken for several reasons including symptomatic patients requiring hospital admission, or general inpatient screening, which includes asymptomatic patients. Furthermore, the algorithm used to flag inpatient status may not necessarily indicate inpatient care in all cases. For example, some tests flagged as coming from "acute" trusts will likely not be inpatients, since these trusts may also perform tests on behalf of GPs and others, and tests requested by A&E may be for patients who are not then admitted.

The flow chart below illustrates the logic used by PHE to generate an indicator of whether a test result was obtained from a hospital inpatient or not (depicted as the "origin" field in the covid19\_result table). The fields used to construct the "origin" field have also been released to enable researchers to replicate it and construct their own alternatives if desired.

PHE's designation of inpatient status can be compared to hospital episodes statistics (HES) dates of admission and discharge made by NHS trusts. A comparison between SARS-CoV-2 positive inpatient status versus inpatient diagnosis codes (ICD-10 diagnosis codes

318 U071 or U072) for Covid-19 (from HES) can also be made. For



#### 321 Propensity score modelling and inverse probability of treatment weighting

322 We calculated propensity scores for a vaccination with BNT162b2 against ChAdOx1 using logistic regression. The variables included in the model were previous Covid-19 infection status (binary), age on the vaccination date (continuous linear), sex (binary), ethnicity (categorial, collected at the UK Biobank 323 recruitment), multiple socio-economic deprivation scores (Townsend deprivation index, income score, employment score, health score, education score, 324 325 housing score, and crime score; continuous linear, collected at the UK Biobank recruitment), education levels (categorial, collected at the UK Biobank recruitment), body mass index (continuous linear, collected at the UK Biobank recruitment), a list of pre-specified medications (binary, obtained from 326 327 primary care prescription records), the number of hospital admissions (continuous linear, obtained from HES), and comorbidities (binary, obtained from primary care diagnosis records). The weights for each participant were then computed based on the Rosenbaum formula:  $Wi = \frac{Zi}{ei} + \frac{(1-Zi)}{(1-ei)}$ .<sup>27</sup> To reduce 328 unstable estimate due to extreme weights in the tails of the propensity score distribution, we used asymmetric trimming to exclude people whose 329 propensity score was below the 1<sup>th</sup> percentile of the propensity score of the BNT162b2cohort and above the 99<sup>th</sup> percentile of the propensity score of the 330 ChAdOx1 cohort.28 331

332

#### 334 Acknowledgements and funding

335 DPA is funded through an NIHR Senior Research Fellowship (Grant number SRF-2018-11-ST2-004).

336 The views expressed in this publication are those of the author(s) and not necessarily those of the

337 NHS, the National Institute for Health Research or the Department of Health. Mr Junqing Xie has

been awarded a Jardine-Oxford Graduate Scholarship and a titular Clarendon Fund Scholarship

339 outside the submitted work. AP-U is supported by the Medical Research Council (grant numbers

- 340 MR/K501256/1, MR/N013468/1).
- 341

### 342 Conflict of Interests Statement

343 Dr Prieto-Alhambra reported receiving grant support from Les Laboratoires Servier; that his research

344 group has received grants and advisory or speaker fees from Amgen, Astellas, AstraZeneca, Chesi-

345 Taylor, Johnson and Johnson and UCD; and that Janssen, on behalf of Innovative Medicines

346 Initiative-funded European Health Data Evidence Network and European Medical Information

347 Framework consortium and Synapse Management Partners, has supported training programs, open

- to external participants, organized by his department. Others have nothing to disclose.
- 349

350

352	Ref	ferences
353	1	Polack FP. Thomas SI. Kitchin N. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19
354	-	Vaccine. <i>N Engl J Med.</i> 2020:383(27):2603-2615. doi:10.1056/NEJMoa2034577.
355	2	Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2
356		Vaccine. N Engl J Med. 2020;384(5):403-416. doi:10.1056/NEJMoa2035389.
357	3	Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
358		(AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
359		South Africa, and the UK. The Lancet. 2020;397(10269):99-111. doi:10.1016/S0140-
360		6736(20)32661-1.
361	4	Sadoff J, Gray G, an Vandebosch, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine
362		against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/NEJMoa2101544.
363	5	Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass
364		Vaccination Setting. N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765.
365	6	Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination
366		roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The
367		Lancet. 2021;397(10285):1646-1657. doi:10.1016/S0140-6736(21)00677-2.
368	7	Pijls BG, Jolani S, Atherley A, et al. Demographic risk factors for COVID-19 infection, severity,
369		ICU admission and death: a meta-analysis of 59 studies. <i>BMJ Open</i> . 2021;11(1):e044640.
370	0	doi:10.1136/bmjopen-2020-044640.
3/1	8	Peckham H, Gruijter NM de, Raine C, et al. Male sex identified by global COVID-19 meta-
372		analysis as a risk factor for death and ITU admission. Nat Commun. 2020;11(1):6317.
3/3	0	dol:10.1038/541467-020-19741-6.
374 275	9	Mathur R, Refitsch CT, Morton CE, et al. Ethnic differences in SARS-COV-2 infection and COVID-
276		England: an observational sobort study using the OpenSAEELV platform. The Langet
370		2021-397/10286)-1711_1724_doi-10_1016/S0140_6736/21)00634_6
378	10	Recalde M. Pistillo A. Fernandez-Bertolin S. et al. Body Mass Index and Risk of COVID-19
379	10	Diagnosis Hospitalization and Death: A Cohort Study of 2 524 926 Catalans <i>J Clin Endocrinol</i>
380		<i>Metab.</i> 2021:106(12):e5030-e5042. doi:10.1210/clinem/dgab546.
381	11	Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus
382		homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine
383		(Com-COV): a single-blind, randomised, non-inferiority trial. The Lancet. 2021;398(10303):856-
384		869. doi:10.1016/S0140-6736(21)01694-9.
385	12	Duarte-Salles T, Prieto-Alhambra D. Heterologous vaccine regimens against COVID-19. The
386		Lancet. 2021;398(10295):94-95. doi:10.1016/S0140-6736(21)01442-2.
387	13	Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of
388		BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label,
389		randomised, controlled, phase 2 trial. The Lancet. 2021;398(10295):121-130.
390		doi:10.1016/S0140-6736(21)01420-3.
391	14	Hulme WJ, Williamson EJ, Green A, et al. Comparative effectiveness of ChAdOx1 versus
392		BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study
393		using OpenSAFELY. <i>medRxiv</i> . 2021:2021.10.13.21264937. doi:10.1101/2021.10.13.21264937.
394	15	Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related
395		Characteristics of UK Biobank Participants With Those of the General Population. American
396		Journal of Epidemiology. 2017;186(9):1026-1034. doi:10.1093/aje/kwx246.
397	16	Cromer D, Steain M, Reynaldi A, et al. SARS-CoV-2 variants: levels of neutralisation required for
398		protective immunity; 2021.

17	Bernal JL. Andrews N. Gower C. et al. Effectiveness of COVID-19 vaccines against the B.1.617.2
	variant; 2021.
18	Lewnard JA, Patel MM, Jewell NP, et al. Theoretical Framework for Retrospective Studies of the
	Effectiveness of SARS-CoV-2 Vaccines. Epidemiology (Cambridge, Mass.). 2021;32(4):508-517.
	doi:10.1097/EDE.00000000001366.
19	King C, Beard J, Crampin AC, et al. Methodological challenges in measuring vaccine
	effectiveness using population cohorts in low resource settings. Vaccine. 2015;33(38):4748-
	4755. doi:10.1016/j.vaccine.2015.07.062.
20	UK COVID-19 vaccines delivery plan.
	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_dat
	a/file/951928/uk-covid-19-vaccines-delivery-plan-final.pdf. Accessed September 27, 2021.
21	Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. GOV.UK. Updated December 2,
	2020. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-
	vaccine-for-covid-19. Accessed September 27, 2021.
22	Regulatory approval of Vaxzevria (previously COVID-19 Vaccine AstraZeneca). GOV.UK. Updated
	December 30, 2020. https://www.gov.uk/government/publications/regulatory-approval-of-
	covid-19-vaccine-astrazeneca. Accessed September 27, 2021.
23	Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and
	genomic data. Nature. 2018;562(7726):203-209. doi:10.1038/s41586-018-0579-z.
24	Armstrong J, Rudkin JK, Allen N, et al. Dynamic linkage of COVID-19 test results between Public
	Health England's Second Generation Surveillance System and UK Biobank. Microbial Genomics.
	2020;6(7). doi:10.1099/mgen.0.000397.
25	Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of
	Confounding in Observational Studies. <i>Multivariate Behavioral Research</i> . 2011;46(3):399-424.
	doi:10.1080/00273171.2011.568786.
26	Wang Y, Cai H, Li C, et al. Optimal caliper width for propensity score matching of three
	treatment groups: a Monte Carlo study. <i>PLOS ONE</i> . 2013;8(12):e81045.
	doi:10.1371/journal.pone.0081045.
27	Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full
	matching on the propensity score in the presence of model misspecification when estimating
	the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26(4):1654-1670.
	doi:10.11///0962280215584401.
28	Sturmer T, Kotnman KJ, Avorn J, Glynn KJ. Treatment effects in the presence of unmeasured
	contounding: dealing with observations in the tails of the propensity score distributiona
	simulation study. American Journal of Epiaemiology. 2010;172(7):843-854.
	dol:10.1093/aJe/kwq198.
	17 18 19 20 21 22 23 24 25 26 27 28